OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

August 17th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Dr. Kaplan on the Treatment of Pediatric Patients With Sarcoma

August 17th 2018

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

August 17th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Savin on the Challenges of Developing Biosimilar Clinical Trials

August 17th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer

August 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer

August 17th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer

August 17th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.

Dr. Holstein Discusses Triplets and Quadruplets in Myeloma

August 17th 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the use of triplets and quadruplets in the treatment of patients with multiple myeloma.

Dr. Bekaii-Saab Discusses the FDA Approval of Lenvatinib in HCC

August 16th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

Dr. Papadimitrakopoulou on Importance of More Targeted Therapies in NSCLC

August 16th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the need for more targeted therapies in non–small cell lung cancer.

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

August 16th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.

Dr. Roschewski on the Treatment of Burkitt Lymphoma in Adults

August 16th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the treatment of Burkitt lymphoma in adult patients.

Dr. Kolberg Discusses Next Steps with ABP 980

August 16th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses next steps with the trastuzumab (Herceptin) biosimilar ABP 980.

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

August 15th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Dr. Jotte on the Optimal Frequency of Lung Cancer Screening

August 15th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the optimal frequency of lung cancer screening.

Dr. Ahn on Biomarker-Driven Strategies in Gastric/GEJ Cancers

August 15th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Dr. Feliciano on ROS1-Targeted Therapy in NSCLC

August 15th 2018

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses ROS1-targeted therapy in patients with non–small cell lung cancer (NSCLC).

Dr. Ligibel on Patient Education to Avoid Breast Cancer Recurrence

August 15th 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women's Cancer at the Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the resources available for patients to educate themselves on avoiding breast cancer recurrence.

Dr. Formenti Discusses Immunology in Breast Cancer Treatment

August 15th 2018

Silvia Chiara Formenti, MD, chairman, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses immunology in the breast cancer treatment landscape.

Dr. George Discusses an Analysis of the S-TRAC Study in RCC

August 15th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses an analysis of the S-TRAC study in renal cell carcinoma.